The Experts below are selected from a list of 2763 Experts worldwide ranked by ideXlab platform
Thomas L Abell - One of the best experts on this subject based on the ideXlab platform.
-
tu1487 progressive occlusion of mesenteric artery changes biomagnetic signature of intestinal slow wave
2012Co-Authors: P J Pasricha, Henry P Parkman, Thomas L Abell, Aynur Unalp, Gayane Yenokyan, Kenneth L Koch, William L Hasler, William J Snape, Linda Anh B Nguyen, Richard W. MccallumAbstract:G A A b st ra ct s research. Oral Domperidone has been reported in some cases to prolong the QT interval and predispose to ventricular arrhythmias (Reddymasu et al. Am J Gastro 2007;102:20362045). The aims: 1) To establish an indications and clinical profile of patients receiving Domperidone through the limited access protocol 2) to investigate possible side effects of Domperidone 3) to analyze ECG reports and the duration of QT intervals. Methods: Study involved a retrospective chart review of 163 patients referred to a single physician at the tertiary GI Motility Center. Patients demographics, GI diagnosis, cardiovascular complain and ECG tracings were obtained. Prolonged QTc were verified if they were longer than 470 ms in females and longer than 450 ms in male patients. Results: Overall 23 out of 163 (13%) patients (15 F; mean age 47, range 18-73) presenting with chief complaints of nausea and vomiting were enrolled in FDA approved protocol and received doses of Domperidone ranging from 10 to 30mg QID for at least 6 up to 12 months. 8 (36%) patients were Hispanic, 12 (52%) Caucasian, and 3(12%) African American. A total 16 (60%) of these patients (9F) were diagnosed with GP, 4 females met the criteria for Cyclic Vomiting Syndrome and 3 patients had symptoms of unexplained nausea. 6 (27%) ECG reports showed non-significant sinus arrhythmias, and one male patient had an irregular rhythm. Women had mean heart rates of 82 (range 52-112) and men's average HR was 86 (range 55-105) bpm. Overall the mean value of QTc for all Domperidone patients was 427 ms (ranges 383 507 ms). Further analysis of ECGs for females showed, mean QTc duration of 425 (394-507) ms and in males it was 429 (383-469) ms. Two patients (9%), one of each gender, had QTc prolongation above the normal respected value. No patients complained about palpitation or cardiac/ chest pain. Two patients noticed breast discomfort. No other potential adverse events including extra-pyramidal side effects were reported during this investigation. Conclusions:1) Domperidone is legally available in USA under the FDAIND approved protocol and can be prescribed for patients with symptoms of nausea and vomiting related to gastroparesis and other motility disorders 2) No clinically relevant cardiac complaints and ECG changes including QTc prolongations were discovered during this observation 3) Domperidone can be regarded as a safe prokinetic and antiemetic agent.
-
making a case for Domperidone in the treatment of gastrointestinal motility disorders
Current Opinion in Pharmacology, 2006Co-Authors: Naveed Ahmad, Jeanne Keithferris, Elizabeth Gooden, Thomas L AbellAbstract:There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis. Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis. Its use, however, has recently become controversial owing to safety concerns, and it has never been approved for marketing by the FDA. During the 1990s, Domperidone was available to US gastroenterologists under a compassionate-use program by Janssen Pharmaceutica, as the manufacturer worked towards, and fell short of, full US market approval. Medical studies, trials and case reports demonstrate the superior efficacy of Domperidone when compared with placebo and other pharmaceutical therapies available. Data on the cardiac toxicity associated with oral use of Domperidone fail to be convincing.
Marsha Campbellyeo - One of the best experts on this subject based on the ideXlab platform.
-
enhancing human milk production with Domperidone in mothers of preterm infants
Journal of Human Lactation, 2017Co-Authors: Elizabeth Asztalos, Marsha Campbellyeo, Orlando Da Silva, Shinya Ito, Alex Kiss, David KnoppertAbstract:Background:Mothers of preterm infants often are at risk of expressing an inadequate amount of milk for their infants and the use of galactogogues is often considered. Domperidone is a widely used galactogogue with little information available to guide clinicians regarding initiation, timing, and duration of treatment.Research aim:The primary objective of this study was to determine whether administration of Domperidone within the first 21 days after delivery would lead to a higher proportion of mothers achieving a 50% increase in the volume of milk at the end of 14 days of treatment compared with mothers receiving placebo.Methods:Eligible mothers were randomized to one of two treatment arms: Group A—Domperidone 10 mg orally three times daily for 28 days; or Group B—placebo 10 mg orally three times daily for 14 days followed by Domperidone 10 mg orally three times daily for 14 days.Results:A total of 90 mothers of infants ≤ 29 weeks gestation were randomized. Mean milk volumes at entry were similar for bot...
-
effect of Domperidone on the composition of preterm human breast milk
Pediatrics, 2010Co-Authors: Marsha Campbellyeo, Alexander C Allen, K S Joseph, Joyce M Ledwidge, Kim Caddell, Victoria M Allen, Kent C DooleyAbstract:OBJECTIVE: Domperidone is increasingly prescribed to improve breast milk volume despite a lack of evidence regarding its effects on breast milk composition. We examined the effect of Domperidone on the nutrient composition of breast milk. PATIENTS AND METHODS: Forty-six mothers who had delivered infants at RESULTS: Maternal and infant characteristics, serum prolactin level, and breast milk volume and composition were not significantly different between Domperidone and placebo groups on day 0. By day 14, breast milk volumes increased by 267% in the Domperidone-treated group and by 18.5% in the placebo group (P = .005). Serum prolactin increased by 97% in the Domperidone group and by 17% in the placebo group (P = .07). Mean breast milk protein declined by 9.6% in the Domperidone group and increased by 3.6% in the placebo group (P = .16). Changes in energy, fat, carbohydrate, sodium, and phosphate content were also not significantly different between groups. Significant increases were observed in breast milk carbohydrate (2.7% vs −2.7%; P = .05) and calcium (61.8% vs −4.4%; P = .001) in the Domperidone versus placebo groups. No significant adverse events were observed among mothers or infants. CONCLUSION: Domperidone increases the volume of breast milk of preterm mothers experiencing lactation failure, without substantially altering the nutrient composition.
Kent C Dooley - One of the best experts on this subject based on the ideXlab platform.
-
effect of Domperidone on the composition of preterm human breast milk
Pediatrics, 2010Co-Authors: Marsha Campbellyeo, Alexander C Allen, K S Joseph, Joyce M Ledwidge, Kim Caddell, Victoria M Allen, Kent C DooleyAbstract:OBJECTIVE: Domperidone is increasingly prescribed to improve breast milk volume despite a lack of evidence regarding its effects on breast milk composition. We examined the effect of Domperidone on the nutrient composition of breast milk. PATIENTS AND METHODS: Forty-six mothers who had delivered infants at RESULTS: Maternal and infant characteristics, serum prolactin level, and breast milk volume and composition were not significantly different between Domperidone and placebo groups on day 0. By day 14, breast milk volumes increased by 267% in the Domperidone-treated group and by 18.5% in the placebo group (P = .005). Serum prolactin increased by 97% in the Domperidone group and by 17% in the placebo group (P = .07). Mean breast milk protein declined by 9.6% in the Domperidone group and increased by 3.6% in the placebo group (P = .16). Changes in energy, fat, carbohydrate, sodium, and phosphate content were also not significantly different between groups. Significant increases were observed in breast milk carbohydrate (2.7% vs −2.7%; P = .05) and calcium (61.8% vs −4.4%; P = .001) in the Domperidone versus placebo groups. No significant adverse events were observed among mothers or infants. CONCLUSION: Domperidone increases the volume of breast milk of preterm mothers experiencing lactation failure, without substantially altering the nutrient composition.
Naveed Ahmad - One of the best experts on this subject based on the ideXlab platform.
-
making a case for Domperidone in the treatment of gastrointestinal motility disorders
Current Opinion in Pharmacology, 2006Co-Authors: Naveed Ahmad, Jeanne Keithferris, Elizabeth Gooden, Thomas L AbellAbstract:There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis. Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis. Its use, however, has recently become controversial owing to safety concerns, and it has never been approved for marketing by the FDA. During the 1990s, Domperidone was available to US gastroenterologists under a compassionate-use program by Janssen Pharmaceutica, as the manufacturer worked towards, and fell short of, full US market approval. Medical studies, trials and case reports demonstrate the superior efficacy of Domperidone when compared with placebo and other pharmaceutical therapies available. Data on the cardiac toxicity associated with oral use of Domperidone fail to be convincing.
N Mishra - One of the best experts on this subject based on the ideXlab platform.
-
spectrophotometric method for simultaneous estimation of paracetamol and Domperidone in tablet formulation
Asian Journal of Research in Chemistry, 2009Co-Authors: Kapil Kalra, S Naik, Garima Jarmal, N MishraAbstract:The development of Vireodt's method for simultaneous estimation of paracetamol and Domperidone involves absorbance measurement at 250 nm and 285 nm corresponding to the respective absorption maxima. Both the drugs obey Beer Lambert's law in the range of 5–30 μg/ml for paracetamol and 0.8–5 μg/ml for Domperidone. The tablet formulation (Grenil, KAPL) was evaluated for the percent content of both the drugs at the selected wavelengths. The method developed was validated to determine its accuracy, precision, specificity and ruggedness. The recovery study was carried out by standard addition method. The average percent recovery was found to be 99.45±0.47 for paracetamol and 100.67±0.18 for Domperidone